Trastuzumab Deruxtecan in Anti–Human Epidermal Growth Factor Receptor 2 Treatment–Naive Patients With Human Epidermal Growth Factor Receptor 2–Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial
November 1, 2022
Her2-low is here to stay. Expect further studies on Enhertu and Trodelvy on gastroesophageal Her-2 low patients. Response rates were modest however, so temper expectations as single agent therapy. I look forward to trials on future combination therapy.
